ProPhase Labs (NASDAQ:PRPH) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of ProPhase Labs (NASDAQ:PRPH) to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of ProPhase Labs in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

ProPhase Labs Stock Down 15.4%

Shares of NASDAQ PRPH opened at $0.52 on Friday. ProPhase Labs has a 52-week low of $0.50 and a 52-week high of $9.35. The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14. The stock has a market cap of $2.40 million, a P/E ratio of -1.33 and a beta of -0.66. The firm has a 50 day moving average price of $0.28 and a 200 day moving average price of $0.36.

ProPhase Labs (NASDAQ:PRPH) last posted its earnings results on Wednesday, November 19th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05). ProPhase Labs had a negative return on equity of 482.05% and a negative net margin of 825.01%.The firm had revenue of $0.88 million during the quarter, compared to analyst estimates of $5.69 million. Analysts expect that ProPhase Labs will post -1.27 EPS for the current year.

Hedge Funds Weigh In On ProPhase Labs

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PRPH. XTX Topco Ltd acquired a new stake in shares of ProPhase Labs in the 2nd quarter valued at about $40,000. Apollon Wealth Management LLC acquired a new stake in ProPhase Labs in the 3rd quarter valued at approximately $84,000. Josh Arnold Investment Consultant LLC acquired a new stake in ProPhase Labs in the 1st quarter valued at approximately $100,000. Accretive Wealth Partners LLC bought a new stake in ProPhase Labs in the 3rd quarter valued at approximately $114,000. Finally, Susquehanna International Group LLP boosted its position in ProPhase Labs by 290.1% during the 3rd quarter. Susquehanna International Group LLP now owns 397,914 shares of the company’s stock worth $182,000 after acquiring an additional 295,899 shares during the last quarter. 9.45% of the stock is owned by institutional investors and hedge funds.

About ProPhase Labs

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.